A molecular model of type I allergy

Identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcεRI interaction and reacts with receptor-bound IgE

Sylvia Laffer, Erik Hogbom, Kenneth H. Roux, Wolfgang R. Sperr, Peter Valent, Hans C. Bankl, Luca Vangelista, Franz Kricek, Dietrich Kraft, Hans Grönlund, Rudolf Valenta

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: The IgE-mediated activation of effector cells and antigen-presenting cells through the high-affinity receptor for IgE (FcεRI) represents a key pathomechanism in type I allergy and many forms of asthma. Objective: We sought to establish an in vitro molecular model for the interaction of human FcεRI, IgE, and the corresponding allergen and to identify monoclonal anti-human IgE anti-bodies with a therapeutic profile different from previously established anti-IgE antibodies. Methods: Human FcεRI α chain, a human monoclonal allergen-specific IgE antibody (chimeric Bip 1), and the corresponding allergen, the major birch pollen allergen Bet v 1, were produced as recombinant proteins and analyzed by means of circular dichroism and native overlays, respectively. Using this molecular model, as well as negative stain immunoelectron microscopic analysis, and in vitro cultivated human basophils, we characterized mouse anti-human IgE antibodies. Results: We established a molecular model for the interaction of human IgE with FcεRI. Using this molecular model, we identified a nonanaphylactic anti-human IgE antibody fragment (Fab12), which blocked the IgE-FcεRI interaction and reacted with effector cell-bound IgE. Conclusion: Fab12 represents a candidate molecule for therapy of atopy and asthma because it can be used for the depletion of circulating IgE antibodies, as well as for the depletion of IgE-bearing cells.

Original languageEnglish
Pages (from-to)409-416
Number of pages8
JournalJournal of Allergy and Clinical Immunology
Volume108
Issue number3
DOIs
Publication statusPublished - 2001
Externally publishedYes

Fingerprint

IgE Receptors
Immunoglobulin Fragments
Molecular Models
Immunoglobulin E
Hypersensitivity
Allergens
Asthma
Betula
Basophils
anti-IgE antibodies
Antibodies
Antigen-Presenting Cells
Circular Dichroism
Pollen
Recombinant Proteins
Coloring Agents
Therapeutics

Keywords

  • Allergy
  • Asthma
  • Competitor
  • FcεRI
  • IgE
  • Therapy

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this

A molecular model of type I allergy : Identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcεRI interaction and reacts with receptor-bound IgE. / Laffer, Sylvia; Hogbom, Erik; Roux, Kenneth H.; Sperr, Wolfgang R.; Valent, Peter; Bankl, Hans C.; Vangelista, Luca; Kricek, Franz; Kraft, Dietrich; Grönlund, Hans; Valenta, Rudolf.

In: Journal of Allergy and Clinical Immunology, Vol. 108, No. 3, 2001, p. 409-416.

Research output: Contribution to journalArticle

Laffer, Sylvia ; Hogbom, Erik ; Roux, Kenneth H. ; Sperr, Wolfgang R. ; Valent, Peter ; Bankl, Hans C. ; Vangelista, Luca ; Kricek, Franz ; Kraft, Dietrich ; Grönlund, Hans ; Valenta, Rudolf. / A molecular model of type I allergy : Identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcεRI interaction and reacts with receptor-bound IgE. In: Journal of Allergy and Clinical Immunology. 2001 ; Vol. 108, No. 3. pp. 409-416.
@article{526ebd0869be45f5bbe88b1d712536d0,
title = "A molecular model of type I allergy: Identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcεRI interaction and reacts with receptor-bound IgE",
abstract = "Background: The IgE-mediated activation of effector cells and antigen-presenting cells through the high-affinity receptor for IgE (FcεRI) represents a key pathomechanism in type I allergy and many forms of asthma. Objective: We sought to establish an in vitro molecular model for the interaction of human FcεRI, IgE, and the corresponding allergen and to identify monoclonal anti-human IgE anti-bodies with a therapeutic profile different from previously established anti-IgE antibodies. Methods: Human FcεRI α chain, a human monoclonal allergen-specific IgE antibody (chimeric Bip 1), and the corresponding allergen, the major birch pollen allergen Bet v 1, were produced as recombinant proteins and analyzed by means of circular dichroism and native overlays, respectively. Using this molecular model, as well as negative stain immunoelectron microscopic analysis, and in vitro cultivated human basophils, we characterized mouse anti-human IgE antibodies. Results: We established a molecular model for the interaction of human IgE with FcεRI. Using this molecular model, we identified a nonanaphylactic anti-human IgE antibody fragment (Fab12), which blocked the IgE-FcεRI interaction and reacted with effector cell-bound IgE. Conclusion: Fab12 represents a candidate molecule for therapy of atopy and asthma because it can be used for the depletion of circulating IgE antibodies, as well as for the depletion of IgE-bearing cells.",
keywords = "Allergy, Asthma, Competitor, FcεRI, IgE, Therapy",
author = "Sylvia Laffer and Erik Hogbom and Roux, {Kenneth H.} and Sperr, {Wolfgang R.} and Peter Valent and Bankl, {Hans C.} and Luca Vangelista and Franz Kricek and Dietrich Kraft and Hans Gr{\"o}nlund and Rudolf Valenta",
year = "2001",
doi = "10.1067/mai.2001.117593",
language = "English",
volume = "108",
pages = "409--416",
journal = "Journal of Allergy and Clinical Immunology",
issn = "0091-6749",
publisher = "Mosby Inc.",
number = "3",

}

TY - JOUR

T1 - A molecular model of type I allergy

T2 - Identification and characterization of a nonanaphylactic anti-human IgE antibody fragment that blocks the IgE-FcεRI interaction and reacts with receptor-bound IgE

AU - Laffer, Sylvia

AU - Hogbom, Erik

AU - Roux, Kenneth H.

AU - Sperr, Wolfgang R.

AU - Valent, Peter

AU - Bankl, Hans C.

AU - Vangelista, Luca

AU - Kricek, Franz

AU - Kraft, Dietrich

AU - Grönlund, Hans

AU - Valenta, Rudolf

PY - 2001

Y1 - 2001

N2 - Background: The IgE-mediated activation of effector cells and antigen-presenting cells through the high-affinity receptor for IgE (FcεRI) represents a key pathomechanism in type I allergy and many forms of asthma. Objective: We sought to establish an in vitro molecular model for the interaction of human FcεRI, IgE, and the corresponding allergen and to identify monoclonal anti-human IgE anti-bodies with a therapeutic profile different from previously established anti-IgE antibodies. Methods: Human FcεRI α chain, a human monoclonal allergen-specific IgE antibody (chimeric Bip 1), and the corresponding allergen, the major birch pollen allergen Bet v 1, were produced as recombinant proteins and analyzed by means of circular dichroism and native overlays, respectively. Using this molecular model, as well as negative stain immunoelectron microscopic analysis, and in vitro cultivated human basophils, we characterized mouse anti-human IgE antibodies. Results: We established a molecular model for the interaction of human IgE with FcεRI. Using this molecular model, we identified a nonanaphylactic anti-human IgE antibody fragment (Fab12), which blocked the IgE-FcεRI interaction and reacted with effector cell-bound IgE. Conclusion: Fab12 represents a candidate molecule for therapy of atopy and asthma because it can be used for the depletion of circulating IgE antibodies, as well as for the depletion of IgE-bearing cells.

AB - Background: The IgE-mediated activation of effector cells and antigen-presenting cells through the high-affinity receptor for IgE (FcεRI) represents a key pathomechanism in type I allergy and many forms of asthma. Objective: We sought to establish an in vitro molecular model for the interaction of human FcεRI, IgE, and the corresponding allergen and to identify monoclonal anti-human IgE anti-bodies with a therapeutic profile different from previously established anti-IgE antibodies. Methods: Human FcεRI α chain, a human monoclonal allergen-specific IgE antibody (chimeric Bip 1), and the corresponding allergen, the major birch pollen allergen Bet v 1, were produced as recombinant proteins and analyzed by means of circular dichroism and native overlays, respectively. Using this molecular model, as well as negative stain immunoelectron microscopic analysis, and in vitro cultivated human basophils, we characterized mouse anti-human IgE antibodies. Results: We established a molecular model for the interaction of human IgE with FcεRI. Using this molecular model, we identified a nonanaphylactic anti-human IgE antibody fragment (Fab12), which blocked the IgE-FcεRI interaction and reacted with effector cell-bound IgE. Conclusion: Fab12 represents a candidate molecule for therapy of atopy and asthma because it can be used for the depletion of circulating IgE antibodies, as well as for the depletion of IgE-bearing cells.

KW - Allergy

KW - Asthma

KW - Competitor

KW - FcεRI

KW - IgE

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0034827566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034827566&partnerID=8YFLogxK

U2 - 10.1067/mai.2001.117593

DO - 10.1067/mai.2001.117593

M3 - Article

VL - 108

SP - 409

EP - 416

JO - Journal of Allergy and Clinical Immunology

JF - Journal of Allergy and Clinical Immunology

SN - 0091-6749

IS - 3

ER -